

Supplementary Figure 1. HLA-DP surface expression on primary AML blasts. AML samples from individual patients (AML111, AML121, AML128) were analyzed cytofluorometrically for surface expression of HLA-DP. Cells were either left untreated (solid black line) or pretreated with IFN- γ (500 IU/mL) for 24 h (black dotted line) before staining with HLA-DP specific mAb. Isotype mAb stained cells served as control (filled black line). MFI values are shown in the following order: Isotype (upper value), untreated (middle value), IFN- γ pretreated (lower value).



Supplementary Figure 2. Anti-leukemic activity of TCR DP04_{chim} modified CD8 T cells in AML engrafted NSG mice. Sublethally irradiated (1.5 Gy) NSG mice were intravenously injected with 4 x 10⁶ primary blasts of AML167 (HLA-DPB1*04:01/17:01). On day 21, when leukemia engraftment reached a level of 1-5 % in bone marrow as confirmed in identically treated control mice, 1 x 10⁷ CD8 T cells retrovirally transduced with TCR DP04_{chim} (n=15) or empty vector(Mock; n=15) were intravenously injected along with single doses of rh IL-2 (1000 U) and FcIL-7 (20 μ g). Animals in the control group without T cells (n=5) only received rh IL-2 and Fc-IL-7. On day 28 (i.e. 7 days after T cell transfer), (A) AML burden (CD45⁺CD33⁺ cells) and (B) T cell frequencies (CD3⁺CD8⁺ cells) were analyzed in bone marrow. Results are pooled from three independent experiments. Symbols represent individual mice and horizontal bars mark mean values with standard deviation.



Supplementary Figure 3. HLA-DP cell surface expression on K562 cells. K562 cells were analyzed for surface expression of HLA-DP by flow cytometry 16-20 h after RNA transfection. Cells were either electroporated with IVT-RNA (10 µg each) encoding for the indicated HLA-DPA1* and -DPB1* alleles (solid black line) or electroporated without RNA (Mock, filled grey line). MFI values for HLA-DP surface staining are shown in the following order: Mock (upper value), HLA-DP electroporated (lower value).



Supplementary Figure 4. Reactivity of clonal CD4 T cells 11G1 against primary fibroblasts. T cells from clonal CD4 population 11G1 were incubated with untreated or IFN- γ pretreated primary fibroblasts from individual HLA-DPB1*03:01 positive and negative donors at an E:T ratio of 0.1:1. IFN- γ spot production was measured after 16-20 h. EBV-LCL from HLA-DPB1*03:01 positive and negative donors served as controls. Standard deviation of mean of two technical replicates is shown.



Supplementary Figure 5. TCR expression of TCR DP03_{chim} redirected T cells. Immunomagnetically selected and prestimulated human CD4 (left panels) and CD8 T cells (right panels) from an HLA-DPB1*03:01 negative healthy donor were transfected with TCR DP03_{chim} coding RNA (CD4 TCR DP03_{chim} and CD8 TCR DP03_{chim}) or without RNA (CD4 Mock and CD8 Mock) and analyzed after 16-20 h by flow cytometry for expression of CD4, CD8, as well as of TCR DP03_{chim} using murine TCR constant β domain (mu TCR C β)-specific mAb.



Supplementary Figure 6. HLA-DP cell surface expression on tumor cell lines. Indicated human (SK29mel, Saos, SW480) and primate (Cos-7) tumor cell lines were analyzed cytofluorometrically for surface expression of HLA-DP 16-20 h after RNA transfection. Cells were either electroporated with IVT-RNA (10 µg each) encoding for HLA-DPA1*01:03 and -DPB1*04:01 alleles (solid black line) or electroporated without RNA (Mock, filled grey line). MFI values for HLA-DP surface staining are shown in the following order: Mock (upper value), HLA-DP electroporated (lower value).